Display options
Cite
Opoku YK, Liu Z, Afrifa J, et al. Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells. EXCLI J. 2020;19:567-581doi: 10.17179/excli2020-1287.
Opoku, Y. K., Liu, Z., Afrifa, J., Kumi, A. K., Liu, H., Ghartey-Kwansah, G., Koranteng, H., Jiang, X., Ren, G., & Li, D. (2020). Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells. EXCLI journal, 19567-581. https://doi.org/10.17179/excli2020-1287
Opoku, Yeboah Kwaku, et al. "Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells." EXCLI journal vol. 19 (2020): 567-581. doi: https://doi.org/10.17179/excli2020-1287
Opoku YK, Liu Z, Afrifa J, Kumi AK, Liu H, Ghartey-Kwansah G, Koranteng H, Jiang X, Ren G, Li D. Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells. EXCLI J. 2020 May 04;19:567-581. doi: 10.17179/excli2020-1287. eCollection 2020. PMID: 32483404; PMCID: PMC7257252.
Copy Download .nbib Format: NLM
Share it on

EXCLI J. 2020 May 04;19:567-581. doi: 10.17179/excli2020-1287. eCollection 2020.

Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells.

EXCLI journal

Yeboah Kwaku Opoku, Zhihang Liu, Justice Afrifa, Asare Kwame Kumi, Han Liu, George Ghartey-Kwansah, Harriet Koranteng, Xinghao Jiang, Guiping Ren, Deshan Li

Affiliations

  1. Department of Biology Education, Faculty of Science Education, University of Education, Winneba, Ghana.
  2. Bio-pharmaceutical Laboratory, College of Life Sciences, Northeast Agricultural University, Harbin 150030, China.
  3. Department of Medical Laboratory Science, University of Cape Coast, Cape Coast, Ghana.
  4. Scientific Research Center, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  5. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Japan.
  6. Department of Biomedical Sciences, University of Cape Coast, Ghana.
  7. Jiamusi University No. 148, Xuefu Road, Jiamusi, Heilongjiang, China.

PMID: 32483404 PMCID: PMC7257252 DOI: 10.17179/excli2020-1287

Abstract

Neurological dysfunction, one of the consequences of acute liver failure (ALF), and also referred to as hepatic encephalopathy (HE), contributes to mortality posing challenges for clinical management. FGF21 has been implicated in the inhibition of cognitive decline and fibrogenesis. However, the effects of FGF21 on the clinical and molecular presentations of HE has not been elucidated. HE was induced by fulminant hepatic failure using thioacetamide (TAA) in male C57BL/6J mice while controls were injected with saline. For two consecutive weeks, mice were treated intraperitoneally with FGF21 (3 mg/kg) while controls were treated with saline. Cognitive, neurological, and activity function scores were recorded. Serum, liver, and brain samples were taken for analysis of CCL5 and GABA by ELISA, and RT qPCR was used to measure the expressions of fibrotic and pro-inflammatory markers. We report significant improvement in both cognitive and neurological scores by FGF21 treatment after impairment by TAA. GABA and CCL5, key factors in the progression of HE were also significantly reduced in the treatment group. Furthermore, the expression of fibrotic markers such as TGFβ and Col1 were also significantly downregulated after FGF21 treatment. TNFα and IL-6 were significantly reduced in the liver while in the brain, TNFα and IL-1 were downregulated. However, both in the liver and the brain, IL-10 was significantly upregulated. FGF21 inhibits CXCR4/CCL5 activation and upregulates the production of IL-10 in the damaged liver stimulating the production pro-inflammatory cytokines and apoptosis of hepatic stellate cells through the STAT3-SOCS3 pathway terminating the underlying fibrosis in HE.

Copyright © 2020 Opoku et al.

Keywords: Thioacetamide (TAA); acute liver failure (ALF); fibrosis; pro-inflammatory cytokines

References

  1. Cell. 2010 Mar 19;140(6):918-34 - PubMed
  2. J Clin Exp Hepatol. 2015 Mar;5(Suppl 1):S21-8 - PubMed
  3. Hepatology. 2010 May;51(5):1675-82 - PubMed
  4. ISRN Hepatol. 2014 Jun 04;2014:236268 - PubMed
  5. Metab Brain Dis. 2001 Jun;16(1-2):37-41 - PubMed
  6. Hepatology. 2014 Sep;60(3):977-89 - PubMed
  7. Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5004-9 - PubMed
  8. PLoS One. 2012;7(5):e36614 - PubMed
  9. Int J Neurosci. 1983 Oct;21(1-2):63-6 - PubMed
  10. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2572-6 - PubMed
  11. Differentiation. 2016 Sep;92(3):84-92 - PubMed
  12. Arterioscler Thromb Vasc Biol. 2011 May;31(5):980-5 - PubMed
  13. Dis Model Mech. 2014 Feb;7(2):193-203 - PubMed
  14. Metab Brain Dis. 2002 Dec;17(4):275-81 - PubMed
  15. Mol Endocrinol. 2010 Oct;24(10):2050-64 - PubMed
  16. J Pharmacol Exp Ther. 2010 Nov;335(2):266-72 - PubMed
  17. Aliment Pharmacol Ther. 2011 Apr;33(7):739-47 - PubMed
  18. J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:56-60 - PubMed
  19. Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):785-90 - PubMed
  20. Nat Rev Nephrol. 2016 Jun;12(6):325-38 - PubMed
  21. Br J Pharmacol. 2009 Oct;158(3):896-906 - PubMed
  22. Front Endocrinol (Lausanne). 2015 Sep 23;6:147 - PubMed
  23. World J Gastroenterol. 2016 Dec 28;22(48):10512-10522 - PubMed
  24. Hepatogastroenterology. 1992 Dec;39(6):542-5 - PubMed
  25. Expert Rev Clin Immunol. 2016 Jun;12(6):661-72 - PubMed
  26. Nat Rev Cancer. 2009 Nov;9(11):798-809 - PubMed
  27. Hepatology. 2014 Aug;60(2):715-35 - PubMed
  28. J Clin Apher. 2016 Jun;31(3):149-62 - PubMed
  29. J Immunol. 2016 Jul 1;197(1):387-9 - PubMed
  30. Clin Gastroenterol Hepatol. 2011 Feb;9(2):181-3 - PubMed
  31. J Neurotrauma. 1996 Oct;13(10):557-68 - PubMed
  32. Horm Behav. 2016 Sep;85:86-95 - PubMed
  33. Breast Cancer Res. 2007;9(3):R32 - PubMed
  34. Nat Med. 2014 Aug;20(8):857-69 - PubMed
  35. Hepatology. 2005 Oct;42(4):854-62 - PubMed
  36. Eur J Pharmacol. 1993 Feb 9;231(2):313-4 - PubMed
  37. Expert Opin Ther Targets. 2013 Dec;17(12):1439-60 - PubMed
  38. Biochim Biophys Acta. 2002 Nov 11;1592(3):345-58 - PubMed
  39. Neurobiol Aging. 2012 Feb;33(2):423.e1-13 - PubMed
  40. Hepatology. 1989 Apr;9(4):594-601 - PubMed
  41. Am J Physiol Gastrointest Liver Physiol. 2017 Mar 1;312(3):G208-G218 - PubMed
  42. Toxicol Appl Pharmacol. 2016 Jan 1;290:43-53 - PubMed
  43. Cell Tissue Res. 2012 Jan;347(1):245-56 - PubMed
  44. Metab Brain Dis. 2013 Jun;28(2):145-50 - PubMed
  45. World J Gastroenterol. 2010 Mar 21;16(11):1304-13 - PubMed
  46. J Neurol Sci. 1999 Nov 30;170(2):138-46 - PubMed

Publication Types